Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma

You may be eligible if

• Diagnosis of multiple myeloma
• * Stage II or III disease
• Relapsed disease after ≥ 2 prior therapies\*, confirmed by the presence of 1 of the following:
• * New lytic lesion
• * A 25% increase in urine or serum monoclonal protein
• Patients who received prior bortezomib must have responded to therapy
• Measurable disease, defined by 1 or more of the following criteria:
• * Serum M-component ≥ 1.0 g/dL by serum protein electrophoresis
• * Urine M-protein excretion \> 200 mg per 24-hour collection, by urine protein electrophoresis
• Performance status - Karnofsky 60-100%
• More than 8 weeks
• Platelet count ≥ 100,000/mm\^3
• Absolute neutrophil count ≥ 1,000/mm\^3
• Bilirubin ≤ 2 mg/dL
• Direct bilirubin ≤ 2 times upper limit of normal (ULN)
• AST or ALT ≤ 2 times ULN
• Creatinine ≤ 1.5 times ULN
• Calcium ≤ 12 mg/dL
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Able to swallow study medication
• Capable of following directions regarding study medication, or has a daily caregiver who will be responsible for administering study medication
• No peripheral neuropathy ≥ grade 2
• No hypersensitivity to any of the following:
• * Bortezomib
• * Boron
• * Mannitol
• * Imidazole compounds (e.g., clotrimazole, ketoconazole, miconazole, econazole)
• No serious medical or psychiatric illness that would preclude study compliance
• No other life-threatening illness (unrelated to tumor)
• No other active or invasive malignancy within the past 3 years except for nonmelanoma skin cancer
• No serious infection
• No prior allogeneic bone marrow transplantation
• More than 30 days since prior and no concurrent immunotherapy
• More than 30 days since prior and no concurrent cytotoxic chemotherapy
• More than 14 days since prior high-dose corticosteroids
• No concurrent therapeutic corticosteroids (e.g., \> 10 mg prednisone per day)
• No concurrent hormonal therapy
• No concurrent antiemetic corticosteroids
• More than 14 days since prior and no concurrent radiotherapy
• More than 1 year since prior bortezomib
• More than 14 days since prior investigational drugs
• No prior tipifarnib
• No other concurrent cancer-related treatment
• No concurrent administration of the following enzyme-inducing anti-epileptic drugs:
• * Phenytoin
• * Phenobarbital
• * Carbamazepine
• No concurrent magnesium- or aluminum-based antacids within 2 hours before or after tipifarnib administration
• Concurrent pamidronate or other bisphosphonates allowed